Active	Status	Sponsor type	Region	Phase	Filter
12 Active 1 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Yue
RaPhLRR, NCT05467891: Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	Recruiting	2	200	US	Ribociclib, Kisqali, Fulvestrant, Faslodex, Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin	Oana Danciu, Novartis Pharmaceuticals	Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer	08/28	08/29